Teva R&D Chief Arik Yoz Departs One Week After Strategy Unveiling
Translated & summarized from Calcalist by baba
Teva Pharmaceuticals announced that Dr. Arik Yoz, its Senior Vice President for Global R&D and Chief Medical Officer, is leaving the company. His departure comes a week after Teva presented its innovative medicines strategy and revenue goals for 2030. Dr. David Gardiner will temporarily lead R&D while Teva searches for a permanent replacement. CEO Richard Francis stated that the company's strategy and goals remain unchanged.
The story in 5 lines · by baba
- Teva's Senior VP of R&D, Dr. Arik Yoz, is departing the company.
- His exit follows Teva's presentation of its innovative medicines strategy and 2030 revenue targets.
- Dr. David Gardiner will temporarily lead R&D operations.
- Teva is actively searching for a permanent replacement for Yoz.
- CEO Richard Francis affirmed that Teva's strategic goals remain unchanged.
Teva Pharmaceuticals announced the departure of Dr. Arik Yoz, its Senior Vice President for Global Research and Development and Chief Medical Officer, just one week after the company presented its development pipeline and revenue targets for innovative medicines through 2030. Yoz is leaving Teva to accept a position elsewhere and will remain with the company for the next few months to assist in the transition of responsibilities.
Dr. David Gardiner, who leads Teva's Innovative Medicines and Clinical Development division, will immediately take over leadership of R&D activities. Gardiner will report directly to Teva President and CEO Richard Francis until a permanent replacement for Yoz is appointed. Teva has stated that it is commencing an immediate search for Yoz's successor.
During its R&D Day on November 11, Teva outlined its progress in developing innovative drugs and set a goal of achieving $6-7 billion in revenue from this sector by 2030. Following the announcement of Yoz's departure, Teva reiterated its commitment to achieving these stated goals. Francis acknowledged Yoz's "significant contribution" to Teva and the transformation of its R&D organization, stating that Yoz helped build the product pipeline, capabilities, and organization presented at R&D Day, leaving Teva in a strong position.
Yoz expressed pride in the R&D organization's achievements in establishing Teva as a truly innovative biopharmaceutical company and in the strong team built. He noted that the progress showcased at R&D Day reflects the organization's strength and the exceptional science developed, thanking the team for their dedication, talent, and partnership.
The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.
Other 2